Status:
ACTIVE_NOT_RECRUITING
MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a randomized pragmatic clinical trial fully embedded in the Swiss Multiple Sclerosis Cohort to assess whether sNfL biomarker monitoring improves patient-relevant outcomes and care of patients ...
Detailed Description
The course of multiple sclerosis (MS) is highly heterogenous with a large variability in symptoms, severity and response to treatment. A large majority of persons with MS are treated with disease modi...
Eligibility Criteria
Inclusion
- Diagnosis of RRMS according to the most recent McDonald criteria (2017) for at least one year
- Have already consented to take part in the SMSC
- Age 18 years old or older
- Able and willing to consent
Exclusion
- Inclusion or planned inclusion in another clinical trial that determines the drug therapy for MS for the purpose of research as these patients are most likely not following the SMSC usual care.
Key Trial Info
Start Date :
February 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2027
Estimated Enrollment :
920 Patients enrolled
Trial Details
Trial ID
NCT06095271
Start Date
February 5 2023
End Date
May 1 2027
Last Update
May 11 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel
Basel, Canton of Basel-City, Switzerland, CH-4031
2
Kantonsspital Aarau
Aarau, Switzerland, CH-5001
3
Inselspital Bern
Bern, Switzerland
4
Hôpitaux Universitaires de Genève
Geneva, Switzerland